key: cord-0780490-wcuf5vzo
authors: Mansouri, Kamran; Rastegari-Pouyani, Mohsen; Ghanbri-Movahed, Maryam; Safarzadeh, Mehrnoush; Kiani, Sara; Ghanbari-Movahed, Zahra
title: Can a metabolism-targeted therapeutic intervention successfully subjugate coronavirus? A scientific rational
date: 2020-08-27
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2020.110694
sha: 90d3e35ce166d96e8edc8ed149adcff3058e77cd
doc_id: 780490
cord_uid: wcuf5vzo

As a process entailing a high turnover of the host cell molecules, viral replication is required for a successful viral infection and requests virus capacity to acquire the macromolecules required for its propagation. To this end, viruses have adopted several strategies to harness cellular metabolism in accordance with their specific demands. Most viruses upregulate specific cellular anabolic pathways and are largely dependent on such alterations. RNA viruses, for example, upregulate both glycolysisand glycogenolysis providing TCA cycle intermediates essential for anabolic lipogenesis. Also, these infections usually induce the PPP, leading to increased nucleotide levels supporting viral replication. SARS-CoV-2 (the cause of COVID-19)that has so far spread from China throughout the world is also an RNA virus. Owing to the more metabolic plasticity of uninfected cells, a promising approach for specific antiviral therapy, which has drawn a lot of attention in the recent years, would be the targeting of metabolic changes induced by viruses. In the current review, we first summarize some of virus-induced metabolic adaptations and then based on these information as well as SARS-CoV-2 pathogenesis, propose a potential therapeutic modality for this calamitous world-spreading virus with the hope of employing this strategy for near-future clinical application.

pathways could be applied to treat this infection. There is evidence reflecting upregulated glycolysis, PPP and TCA cycle following coronavirus infection [7] [8] [9] [10] [11] [12] [13] [14] [15] 16] . Therefore, in the current review, we first summarize some of the virus-induced metabolic adaptations and then, based on this information as well as SARS-CoV-2 pathogenesis, propose a potential therapeutic modality for this calamitous world-spreading virus with the hope of employing this strategy for near-future clinical application.

A plethora of strategies have been adopted by viruses to ensure the undistributed supply of macromolecules and suit the host cell metabolism according to their specific demands. The high turnover of biomolecules linked with virion production as well as simultaneous activation of cellular defense mechanisms brings about a highly anabolic state that is often associated with upregulated uptake of extracellular carbon sources (like glucose and glutamine) as well as their redirection to metabolic pathways vital for viral replication including lipogenesis and nucleotide synthesis [5] .

It has been demonstrated that viruses employ strategies as diverse as the activation of cytosolic signaling, including PI3K [17] and CaMKK1/AMPK [18, 19] or transcriptional regulation like activation of Myc [20, 21] , SREBP [16, [22] [23] [24] [25] and ChREBP [26] . The current data point to a dichotomy between RNA and DNA viruses when delving into their respective strategies of host cell manipulation. That is to say, while DNA viruses have been found to control key metabolic pathways at the transcription level [20, 21, 26] , RNA viruses seem to shape host-cell metabolism through post-transcriptional modifications [17] , that are in concordance with the pace of the respective replication cycles (Fig.1 ).

Host cell FA synthesis machinery has proven substantial for viral genome replication, virion production, and morphogenesis. Numerous viruses instigate the formation of phosphatidylinositol 4phosphate/cholesterol-enriched membranes to create viral replication complexes (VRCs) at the interface of the host endoplasmic reticulum (ER). Generation of secluded membranes that protect viral nucleic acids from immune surveillance (for example, cytosolic pattern recognition receptors) and encompass an optimal environment for viral replication, requires the accumulation of sterols at the VRCs of RNA viruses [27, 28] . VRC formation critically relies on the host cell's sterol synthesis reprogramming by recruiting the phosphatidylinositol-4 kinase III beta and oxysterol-binding protein PI3K-dependent trafficking of GLUT1-containing vesicles to the cell membrane, leads to increased glucose uptake and metabolism [5] .

Coronaviruses are pandemic viruses able to cause lethal lung injuries and death from acute respiratory distress syndrome (ARDS) [44] . ARDS characterized by severe hypoxemia, is generally J o u r n a l P r e -p r o o f accompanied by oxidative injury, uncontrolled inflammation, and damage to the alveolar-capillary barrier [45, 46] . Enhanced oxidative stress is a key insult in pulmonary injury including ARDS, as one clinical manifestation of acute respiratory failure with considerably high morbidity and mortality [47] . Therefore, oxidative stress is a dangerous aspect of this infection. Increased extracellular oxidative stress, as a consequence of "cytokine storm", results in ARDS which is the key pathologic cause for the high mortality rate of this pandemic infection.

On such a basis, metabolic intervention in COVID-19 is suggested to follow two main goals: 1) Inhibition of virus replication 2) Inhibition of oxidative stress.

A possible strategy for achieving the first goal is: "targeting lipogenesis" that is required for virus packaging. This goal could be achieved in 3 ways a) downregulating glycolysis to inhibit pyruvate production (in a way other than inhibiting GLUT activity like GLUT1, because they are required to keep the PPP active) and entry into the TCA cycle thereby decreasing lipogenesis. Normally, glycolysis is needed to provide additional intermediates of TCA cycle for anabolic lipogenesis; b) mitochondrial targeting to decrease TCA flux; c) direct inhibition of cellular lipogenesis.

Possible strategies for achieving the second goal include: a) Upregulating the PPP and b) scavenging of extracellular ROS produced during infection (especially at alveolar spaces) Regarding a) upregulating the PPP; Intracellular oxidative stress contributes to coronavirus infectivity and increases its replication in lung epithelial cells. As demonstrated by recent studies, glucose-6-phosphate dehydrogenase (G6PD)-deficient or G6PD-knockout cells (with decreased intracellular redox power as a result of decreased NADPH) exhibit a higher susceptibility to coronavirus infection. Indeed, intracellular oxidative stress provides a proper milieu for coronavirus replication [48] . Also, these cells show a lower capacity to mount antiviral responses [49] . In fact, another reason convincing us to propose targeting of oxidative stress as a therapeutic strategy for coronavirus infection, relates to the previously published reports on the association of G6PD deficiency with coronavirus infectivity (HCoV-229E). As stated before, RNA viruses, in general, upregulate PPP which provides adequate nucleotides levels and redox power (NADPH) for sustained viral replication. Several studies, notwithstanding, made us look at this pathway (in the case of coronaviruses) somehow different and take our general view away of total beneficial effects of this pathway for coronavirus replication. As it is well-established, oxidative phase of PPP, whose key and rate-limiting enzyme is G6PD, plays a J o u r n a l P r e -p r o o f pivotal role in providing cells with sufficient redox power via NADPH production. Thus, cells lacking this key PPP enzyme have lower capacities to counteract oxidative stress. On the other hand, it has been shown that G6PD-deficient cells have a higher susceptibility to HCoV-229E (causative coronavirus of SARS) infection. In a study carried out by Wu et al. in 2008, G6PD-deficient and G6PDknockdown cells showed much higher viral gene expression as well as viral particle production upon infection with HCoV-229E. These phenomena were associated with a higher production of oxidants, representing oxidative stress in host cells as an important factor for coronavirus infectivity.

Furthermore, these researchers demonstrated that antioxidant agents could ameliorate increased viral infection of G6PD-deficient cells. This study provides the evidence that redox status of host cells plays an important role in viral infectivity [48] . Concordant with this report, these researchers in 2015 tried to delineate the underlying mechanism of this interesting phenomenon. They showed that in normal cells, viral infection triggers IκB degradation and hence NF-κB translocation that promotes antiviral responses and inhibits viral replication. But, regarding G6PD-deficient cells, they found a fall in the NADPH/NADP + ratio, which results in the upregulation of HSCARG protein as an NADPH sensor. This protein negatively affects the NF-κB signaling pathway, which is responsible for the expression of the antiviral genes: tumor necrosis factor-alpha (TNF-α) and GTPase myxovirus resistance 1 (MX1). Therefore, its upregulation in G6PD-deficient cells results in impaired antiviral response and, as a consequence, enhanced HCoV-229E replication [49] . PPP is the prime cellular antioxidant defense system [50] . PPP, derived from glycolysis at the first committed step of glucose metabolism, is indispensable for ribonucleotides synthesis and is also a major source of NADPH.

NADPH is required for efficient scavenging of ROS. Indeed, increased PPP can be considered as a cellular mechanism to cope with intracellular oxidative stress as a result of elevated ROS levels.

Therefore, upregulating this pathway and keeping it active in this infection seems essential to reduce the detrimental effects of ROS.

Another evidence indicating the advantage of increased PPP activity in this infection is related to the autophagy process. Autophagy is suggested to play a key role in the replication of coronaviruses Nevertheless, we should keep in mind that increased NADPH as a result of upregulated PPP may be a double-deck sword as NADPH has a dual activity. In addition to serving as a fuel for the antioxidant system, NADPH can exert pro-oxidant effects by acting as a substrate for NADPH oxidases (NOXs) thereby causing lung injuries and favoring SARS-CoV-2 infectivity. On the other hand, polymorphonuclear leukocytes (PMNs) and macrophages, upon infiltrating the inflamed regions through the microvascular blood vessels, can secrete cytotoxic factors including proinflammatory cytokines and ROS. These mediators contribute to the endothelial and epithelial dysfunction leading to fluids leakage from the circulation into the interstitial space and alveoli [56] . Studies have shown that an excess of glucose entry can be diverted through the PPP, which provides additional substrates for NOX thereby resulting in a pro-oxidant environment that exacerbates inflammation

[57]. Thus, increased PPP flux, through providing additional substrates for NOX enzymes, can bring about a pro-oxidant environment aggravating inflammation. Also, NOX1 and NOX2 deletion gives rise to a dramatic decrease in ROS production by macrophages [56] . Accordingly, targeting of NOX represents a proper strategy to not only decrease oxidative stress in the host cells but also mitigate the capacity of macrophages and other inflammatory cell , s for ROS production. On such a basis, it is recommended to utilize a medication that not only upregulates PPP and provides high NADPH levels to counteract oxidative stress but also concomitantly prevents NADPH entry into the mentioned prooxidant pathway via NOX inhibition.

As mentioned above, PPP inhibition leads to autophagy induction. Thus, keeping this pathway active or upregulating it, as suggested in this study, may play a role in reducing autophagy to prevent viral replication.

As stated, glycolysis intervention aims at lipogenesis downregulation. Lipogenesis is required for virus packaging. Glycolysis intervention inhibits pyruvate production and entry into the TCA cycle, thereby decreasing lipogenesis. Normally, glycolysis is needed to provide additional intermediates of the TCA cycle for anabolic lipogenesis; 

As outlined in Table 1 [18, 65-146], our knowledge on the particular changes induced by a given virus has led to numerous strategies for targeting viral replication in cell culture and in vivo models. Therefore, given its very well-established and favorable side effect profile, ascorbic acid (vitamin C) in particular seems to be a promising compound.

Vitamin C or ascorbic acid at high doses has shown alterations in metabolic pathways involving increased upstream glycolysis and PPP metabolites and decreased downstream glycolysis metabolites. Thus, this vitamin can be considered as a glycolysis inhibitor [147] .

Vitamin C, by lowering viral infectivity, can be used as an inactivating agent for DNA and RNA viruses [148, 149] . Additionally, ascorbic acid can detoxify viral products that cause pain and inflammation [150] . It has been shown that high dose intravenous (IV) injection of vitamin C is effective against viral infections including the common cold (rhinovirus) [151] ; influenza [152, 153] ; zika [154] ; and chikungunya [155, 156] . Oral supplementation with vitamin C (at doses over 3 g) also appears to be capable of both preventing and treating respiratory and systemic infections [157] .

Two families of transport proteins, including GLUTs and sodium-dependent vitamin C transporters (SVCTs) 1 and 2, mediate vitamin C uptake. GLUTs, mainly GLUT1 and GLUT3, transport dehydroascorbic acid (DHA) into cells while SVCTs transport reduced vitamin C directly into the cells ( Fig.2) [158, 159] .

The TCA cycle provides the fuel acetyl-CoA for the process of lipogenesis [46] that is crucial for sustained viral propagation. Therefore, targeting lipogenesis could pave the way for effective inhibition of viral replication.

J o u r n a l P r e -p r o o f

As shown in Table 2 [21, , there are many Krebs cycle inhibitors with antiviral properties.

Here, metformin, according to its well-established and favorable side effect profile and antiviral activity [208 -215] , seems to be a promising compound.

As a drug with pleiotropic effects, metformin participates in glucose homeostasis, mostly through inhibiting liver glucose production [216] . Also, 0ne study found that metformin was significantly associated with reduced mortality from COVID-19 [217] . Metformin, by lowering the flow of glucoseand glutamine-derived metabolic intermediates into the TCA cycle leads to decreased citrate production and de novo lipid biosynthesis. Metformin acts directly on mitochondria to restrain TCA cycle activity and oxidative phosphorylation, leading cells to accept less glucose-derived carbon that favors lactic acid production [218] . Metformin brings about energetic stress in cells by inhibiting the complex I of the electron transport chain in mitochondria. This causes decreased NADH oxidation and TCA flux resulting in low levels of TCA metabolites. Therefore, metformin indirectly inhibits cellular lipogenesis (Fig.3) 

On the other hand, metformin also directly hinders lipogenesis. Direct anti-lipogenic activities of metformin are mediated through inhibition of key metabolic enzymes including ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS) complex, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) [220] . Of note, metformin hinders ROS production by suppressing NOX activity [221] . This is a key characteristic with respect to our proposed treatment protocol for COVID-19, as high cellular NADPH levels (as a result of upregulated PPP), by acting as NOX substrate, not only can result in oxidative stress and promote viral replication in the infected cell but also potentiates ROS production by the recruited inflammatory cells at the alveolar spaces contributing to ARDS.

Acute organ failure, particularly pulmonary failure (ARDS), is the major mechanism for COVID-19 related fatality [222, 223] . Substantially increased oxidative stress owing to the rapid release of cytokines and free radicals, etc. is the hallmark of ARDS that results in cellular injury, organ failure, and death [44] . Therefore, early intake of high dose antioxidants, especially vitamin C, plays a crucial role in the management of such patients. Hence, in the case of coronavirus epidemic, all those in the J o u r n a l P r e -p r o o f leadership and those providing direct assistance patients are recommended to rapidly and bravely apply high dose IV vitamin C.

Increased oxidative stress, as a consequence of "cytokine storm," results in ARDS as the key pathologic cause for the high mortality rate of this pandemic viral infection. Cytokine storm-induced ARDS is the key pathoenic event responsible for the death of these patients [44] . IV vitamin C is suggested to effectively cope with cytokine storm-induced oxidative stress (Fig.4) [224] .Vitamin C is a pivotal component of the antioxidant system in cellular response [225] .As a matter of fact, high dose IV vitamin C has been applied clinically successfully in viral ARDS as well as in influenza. In patients receiving mechanical ventilation, dietary antioxidants (vitamin C and sulforaphane) have been shown to decrease oxidative stress-induced acute inflammatory lung injury [229] . Other antioxidants (like curcumin) have also shown promising anti-inflammatory potentials in pneumonia [230] .

Based on these reports, targeting the recalcitrant COVID-19 related oxidative stress with high dose antioxidants (like vitamin C) seems a logical step in the immediate management of this catastrophic pandemic, without the lengthy waiting for pathogen-specific drugs and vaccines. Also, metformin has been shown to decrease ROS and nitric oxide (NO) levels and increase the antioxidant system, such as superoxide dismutase (SOD) [231] .

Vitamin C serves as a mild pro-oxidant capable of producing free radicals and, as a result, induces mitochondrial biogenesis. Mitochondrial biogenesis enhances the metabolic enzymes needed for glycolysis and oxidative phosphorylation, and hence creates a greater mitochondrial metabolic capacity. As shown by a study exploring the effects of azithromycin and doxycycline on the mitochondrial biogenesis, low doses of these antibiotics were able to inhibit mitochondrial biogenesis [232] . Also, azithromycin and doxycycline exhibit antiviral activities [233] [234] [235] [236] [237] [238] [239] [240] [241] .

The pandemic outbreak of the novel coronavirus SARS-CoV-2 in 2020 vigorously necessitates as urgent finding of effective therapeutic agents as possible [242] . At present, there is no definite and effective treatment for SARS-CoV-2 infection. Acute organ failure, especially pulmonary failure (acute respiratory distress syndrome or ARDS), is the key pathogenic mechanism governing SARS-CoV-2 fatality. Significantly increased oxidative stress due to the rapid release of free radicals and cytokines, etc. is the hallmark of ARDS, resulting in cellular injury, organ failure, and finally death [222, 223] . Also, according to the recent publications concerning the higher susceptibility of G6PDdeficient cells to coronavirus (HCoV-229E) infectivity, oxidative stress in host cells provides a proper milieu for coronavirus replication [48] . Therefore, reducing ROS levels in patients with COVID-19 seems a therapeutic strategy against this disease. Another therapeutic strategy is to prevent virus replication. A therapeutic approach incorporating both of these aspects can be considered optimal treatment.

Vitamin C, with its antioxidant properties, is known to reduce ROS. But can it stop the virus replication?

We propose the use of vitamin C for COVID-19 treatment to not only directly counteract the deleterious and dangerous effects of augmented oxidative stress responsible for ARDS in the extracellular space (alveolar space), but also hinder glycolysis and instead upregulate PPP and intracellular NADPH for creating a higher cellular redox status with the aim of lowering SARS-CoV-2 infectivity, as oxidative stress has been elucidated to promote coronavirus infectivity. Also, due to the very recent report on the autophagy-inducing effect of G6PD blockade that causes increased viral replication, we assume that PPP upregulation is likely to cope with SARS-CoV-2 replication through this autophagy-mediated mechanism, too. But further researches in the future remain to fully shed light on this facet of coronavirus infection. Early use of high dose antioxidants, especially vitamin C, therefore, plays a key role in the management of these patients. In a study, modest quantities of supplemental vitamin C (200 mg of vitamin C daily) led to an 80 % reduction in death among severely ill, hospitalized respiratory disease patients [227] . Infants with viral pneumonia administered with vitamin C have shown reduced mortality [243] . In a subgroup of 1,766 patients, moderate doses of vitamin C shortened ICU stay by 97 % [227] . The major danger with SARS-CoV-2 infection is disease progression to SARS and pneumonia. Since the 1940s, medical doctors have successfully used vitamin C against viral pneumonia [244] .

To replicate, RNA viruses upregulate both glycolysis and glycogenolysis, providing their host cells with TCA intermediates required for anabolic lipogenesis. The novel emerged coronavirus, SARS-CoV-2, which has thus far spread from China throughout the world with fatal outcomes, is an RNA J o u r n a l P r e -p r o o f virus as well [6] . Also, evidence points to a higher PPP flux following RNA virus infections [245] , as is the case in the rhinovirus infection, which results in the production of higher nucleotide levels supporting viral replication. On such a basis, inhibition/modulation of these metabolic pathways Vitamin C inhibits glycolysis, which is a metabolic pathway used by cells to convert glucose into energy. As stated, RNA viruses for sustained replication increase glycolysis and glycogenolysis, thereby providing TCA intermediates required for anabolic lipogenesis [245] . Thus, despite the 

As the PPP upregulates, the production of ribonucleotides required for virus replication increases.

Since the virus relies on host cell lipogenesis for its replication, targeting lipogenesis is speculated to inhibit virus replication even in the presence of large amounts of ribonucleotides. In this regard, inhibition of lipogenesis via Krebs cycle blockade seems conceivable. As mentioned above, TCA cycle blockade is required for the inhibition of viral replication. Metformin is introduced for this purpose.

Metformin, not only decreases mitochondrial TCA cycle intermediates but also directly inhibits lipogenesis [219, 220] . Since metformin suppresses NOX activity, its intake would cicumvent the potential hazardous impacts of high intracellular NADPH levels (due to upregulated PPP) in terms of generating higher ROS (contributing to the detrimental function of proinflammatory cells) and creating intracellular oxidative stress (contributing to increased SARS-CoV-2 infectivity in the host cell), as well. On the other hand, vitamin C is a mild pro-oxidant. Therefore, it can produce free radicals and, as a result, induces mitochondrial biogenesis. This can act in favor of SARS-CoV-2 replication by providing the cell with a higher number of factories in charge of TCA cycle flux and consequently lead to increased lipogenesis. To avoid the effect, we propose a strategy to both inhibit mitochondrial biogenesis and hamper mitochondrial protein translation. The use of azithromycin or doxycycline (or both) at low doses (that spares antibiotic resistance) has been shown to prevent mitochondrial biogenesis. Alsoas off-target side effects, azithromycin and doxycycline can inhibit large and small mitochondrial ribosomes, respectively [232] . Additionally, these antibiotics also possess antiviral activities [233] [234] [235] [236] [237] [238] [239] [240] [241] .

A combination of vitamin C, metformin and doxycycline/azithromycin, is suggested to serve as an effective treatment for this infection. As these compounds are non-toxic, we hope that this therapeutic strategy can be applied with minimal side effects. It is worth mentioning that, applying Fig.1 a) Rhinovirus, as an RNA virus (RV), post-transcriptionally modulates the host cell metabolism. Infection with this virus induces anabolic reprogramming of the host cell metabolism by 1) Inducing PI3K-mediated trafficking of GLUT1-containing vesicles to the host cell membrane thereby increasing glucose uptake. Also, overexpression of GLUT1 has been found to result in increased PPP intermediates 2) Upregulating both glycolysis and glycogenolysis which provides TCA cycle intermediates required for anabolic lipogenesis 3) Activating the PPP which results in enhanced levels of nucleotide that support viral replication. RV: rhinovirus; PI3K: phosphatidylinositol 3-kinase; GLUT: glucose transporter; TCA: tricarboxylic acid cycle. b) Schematic overview representing metabolic targets of some DNA viruses. Various DNA viruses activate particular anabolic metabolic programs following infecting the host cells, to finally support viral replication and virion maturation. Dashed arrows show a virus induced activation of the respective metabolic pathway or a transcription factor activation. TCA: tricarboxylic acid cycle; α-KG: α-ketoglutarate; SREBP: sterol regulatory element-binding protein; ChREBP: carbohydrate-response element-binding protein; GLUT: glucose transporter; HCMV: human cytomegalovirus; HSV-1: herpes simplex virus-1; KSHV: Kaposi's sarcoma-associated herpesvirus; VACV: vaccinia virus. Microvascular blood vessels allow elevated infiltration of polymorphonuclear leukocytes (PMNs) and macrophages into the inflamed region followed by increased release of cytotoxic factors including proinflammatory cytokines and ROS. These released mediators contribute to the endothelial and epithelial dysfunction leading to fluids leakage from the circulation into the interstitial space and

Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks

Viral genomics, epidemiology, vaccines, and therapeutic interventions

Viral activation of cellular metabolism

Hijacking the supplies: Metabolism as a novel

The indoleamine 2, 3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes

In vivo potentiation of glutamate-mediated neuronal damage after chronic administration of the glycolysis inhibitor iodoacetate

Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells

The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells

High Km glucose-phosphorylating (glucokinase)

Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes

Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway

Glycolytic enzyme inhibitor therapy in human malignant neoplasia

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers

Ras inhibition in glioblastoma downregulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death

Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells metabolic basis and potential clinical implications

Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death

Sensitization of cultured Chinese hamster cells to 42° C hyperthermia by pentalenolactone, an inhibitor of glycolytic ATP synthesis

A phase I, doseescalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhibitor of glycolysis

Compound C, an inhibitor of AMP-activated protein kinase, inhibits glycolysis in mouse longissimus dorsi postmortem

Effect of a new synthetic complement inhibitor on hepatic glycolytic intermediates in septic rats

Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells

Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells

AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection

Glycolysis, glutaminolysis, and fatty acid synthesis are required for distinct stages of Kaposi's sarcomaassociated herpesvirus lytic replication

Targeting phospholipase D in cancer, infection and neurodegenerative disorders

Phloretin inhibits Zika virus infection by interfering with cellular glucose utilisation

Inhibition of enterovirus 71 replication and viral 3C protease by quercetin

Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry

Antiviral effect of flavonoids on human viruses

A review on flavonoid apigenin: Dietary intake, ADME, antimicrobial effects, and interactions with human gut microbiota

Genistein Has Antiviral Activity against Herpes B Virus and Acts Synergistically with Antiviral Treatments to Reduce Effective Dose

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1

Anti-adenovirus activities of shikonin, a component of Chinese herbal medicine in vitro

Antiviral activity of a synthesized shikonin ester against influenza a (H1N1) virus and insights into its mechanism

The effect of sodium fluoride on experimental influenza virus infection in mice

Reactivation of hepatitis B virus after withdrawal of erlotinib

Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses

Sorafenib impedes rift valley fever virus egress by inhibiting valosin-containing protein function in the cellular secretory pathway

Sorafenib suppresses hepatitis B virus gene expression via inhibiting JNK pathway

Effect of Sorafenib on Hepatitis C Viremia in Cirrhotic Patients With Hepatocellular Carcinoma

HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells

Tryptophan catabolism in chronic viral infections: handling uninvited guests

Metabolic requirements for the development of hemadsorption activity and virus formation in BHK-21 cells infected with Newcastle disease virus

Effect of organic mercury compounds in serological tests on some isometric plant viruses

Iodoacetamide treatment of bovine leukemia virus glycoprotein gp51 enhances the Western blotting reactivity of anti-peptide antibodies

Some effects of iodine and other reagents on the structure and activity of tobacco mosaic virus

Heterogeneity of the respiratory syncytial virus 22K protein revealed by Western blotting with monoclonal antibodies

Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors

The effect of certain enzyme inhibitors on the activity and growth of psittacosis virus

Role of the PI3K-AKT-mTOR pathway in hepatitis B virus infection and replication

Hypericin inhibits hepatitis C virus replication via deacetylation and down-regulation of heme oxygenase-1

Effect of sulfhydryl reagents on the infectivity of vesicular stomatitis virus

HSV-1 enhances the energy metabolism of human umbilical cord mesenchymal stem cells to promote virus infection

The effect of malonate on succinic dehydrogenase

Synthesis, antiviral activity, and 3D-QSAR study of novel chalcone derivatives containing malonate and pyridine moieties

In vivo administration of serum thymic factor (FTS) prevents EMC-D virus-induced diabetes and myocarditis in BALB/cAJcl mice

Further Observations on the Effect of 6-Aminonicotinamide on Chick Embryo Tissue Cultures infected with Vaccinia and other Viruses

Antiviral activities of pentalenolactones

Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection

A flavonoid, luteolin, cripples HIV-1 by abrogation of tat function

Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin

Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression

Luteolin inhibits hepatitis B virus replication through extracellular signal-regulated kinase-mediated down-regulation of hepatocyte nuclear factor 4α expression

Regulation of virus-induced inflammatory response by β-carotene in RAW264. 7 cells

EBV reactivation as a target of luteolin to repress NPC tumorigenesis

Antiviral activity of luteolin against Japanese encephalitis virus

Antichikungunya activity of luteolin and apigenin rich fraction from Cynodon dactylon, Asian Pac

Vitamin C in cancer: a metabolomics perspective

Antiviral and immunomodulatory activities of ascorbic acid

Administration of vitamin C in a patient with herpes zoster-a case report

Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells

Vitamin C and the common cold: a retrospective analysis of Chalmers' review

Ascorbic acid role in containment of the world avian flu pandemic

Vitamin C and severe influenza: a case report

Adrover-López, High dose intravenous vitamin c treatment for zika fever

High dose intraveneous vitamin C and chikungunya fever: a case report

Intravenous ascorbic acid and hydrogen peroxide in the management of patients with chikungunya

Vitamin C and immune function

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH

Vitamin C transporters in cancer: current understanding and gaps in knowledge

Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors

Poly (4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections-Potential as a dual functional microbicide

A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection

Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection

The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses, FRONT MICROBIOL

Inactivation and morphological changes of avian influenza virus by copper ions

Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells

Inhibitions in the citric acid cycle, Metabolic inhibitors-a comprehensive treatise

Pig heart fumarase contains two distinct substrate-binding sites differing in affinity

Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

McCormick Influenza a virus host shutoff disables antiviral stress-induced translation arrest

Monomethylarsonous acid (MMAIII) and arsenite: LD50 in hamsters and in vitro inhibition of pyruvate dehydrogenase

Control of the citric acid cycle by glyoxylate: Mechanism of the inhibition by oxalomalate and γ-hydroxy-α-oxoglutarate

Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetate

3-Bromopyruvic acid inhibits tricarboxylic acid cycle and glutaminolysis in HepG2 cells

The relation of the krebs cycle to viral synthesis: ii. the effect of sodium fluoroacetate on the propagation of influenza virus in mice

Toxicology of fluoroacetate: a review, with possible directions for therapy research

Inhibition of the Krebs cycle by glyoxylic acid

Control of the citric acid cycle by glyoxylate. 1. A new inhibitor of aconitase formed by the condensation of glyoxylate with oxaloacetate

Jonas Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia, Blood

The emerging role and targetability of the TCA cycle in cancer metabolism

Recent development of small molecule glutaminase inhibitors

Antiviral effects of 6-diazo-5-oxo-l-norleucin on replication of herpes simplex virus type 1

Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy

Soluble expression, rapid purification, biological identification of chicken interferon-alpha using a thioredoxin fusion system in E. coli and its antiviral effects to H9N2 avian influenza virus

Thioredoxin, a master regulator of the tricarboxylic acid cycle in plant mitochondria

Studies on the mechanism of alloxan diabetes

The Relation of the Tricarboxylic Acid Cycle to Bacterial Infection: IV. The Effect of Three Metabolic Inhibitors and Salmonella typhimurium on the Citric Acid Content of Mouse Tissues

Light and electron microscopic studies of the rat kidney after administration of inhibitors of the citric acid cycle in vivo: I. Effects of sodium fluoroacetate on the proximal convoluted tubule

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates

Defects in Antiviral T Cell Responses Inflicted by Aging-Associated miR-181a Deficiency

A conserved miRNA-183 cluster regulates the innate antiviral response

mimic inhibits replication of Japanese encephalitis virus in glioblastoma cells

suppresses HBV gene expression and replication by targeting nuclear factor IA

Inhibitory effect and mechanisms of microRNA-146b-5p on the proliferation and metastatic potential of Caski human cervical cancer cells

Influenza A virus-induced downregulation of miR-26a contributes to reduced IFNα/β production

Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity

miR-26a Inhibits Feline Herpesvirus 1 Replication by Targeting SOCS5 and Promoting Type I Interferon Signaling

Revisiting the TCA cycle: signaling to tumor formation

Rescue of TCA Cycle Dysfunction for Cancer Therapy

AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations

Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers

Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of α-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress

In Vitro Preparation of H2O2 Inactivated Rabies Vaccine and Related Immunogenicity

The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance

Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals

Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22

Metformin use and severe dengue in diabetic adults

Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm nonrandomised Lilac pilot study protocol

Targeting liver stage malaria with metformin

Metformin suppressed human cytomegalovirus (hCMV) replication and its potential molecular mechanisms in human fibroblasts

Molecular mechanisms of metformin for diabetes and cancer treatment

Observational study of metformin and risk of mortality in patients hospitalized with Covid-19

Metformin antagonizes cancer cell prolifeation by suppressing mitochondrial-dependent biosynthesis

Metabolic profiles associated with metformin efficacy in cancer, FRONT ENDOCRINOL

Metformin and Pancreatic Cancer Metabolism, Pancreatic Cancer-Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment: Dr

Metformin inhibits lithocholic acidinduced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity, Scientific reports

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Features, Evaluation and Treatment Coronavirus (COVID-19)

ROS signaling in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Pulmonary Vasculature Redox Signaling in Health and Disease

Role of Nrf2 and its activators in respiratory diseases

Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome

Vitamin C can shorten the length of stay in the ICU: a meta-analysis

Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study

Dietary Antioxidants Significantly Attenuate Hyperoxia-Induced Acute Inflammatory Lung Injury by Enhancing Macrophage Function via Reducing the Accumulation of Airway HMGB1

Direct pulmonary delivery of solubilized curcumin reduces severity of lethal pneumonia

Metformin and its antiinflammatory and anti-oxidative effects; new concepts

Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)

Azithromycin induces anti-viral responses in bronchial epithelial cells

Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients

Azithromycin shows anti-Zika virus activity in human glial cells

Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo

Azithromycin for Recurrent Respiratory Tract Infections in Pediatric Populations, Theses, Dissertations and Capstone Projects

Antiviral activity of doxycycline against vesicular stomatitis virus in vitro

Inhibitory effect of doxycycline against dengue virus replication in vitro

A combination of doxycycline and ribavirin alleviated chikungunya infection

Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking

Vitamin C supplementation for prevention and treatment of pneumonia, The Cochrane database of systematic reviews

Vitamin C may affect lung infections

Viral hijacking of cellular metabolism

Aykin-Burns, D. Spitz, 2-deoxy-D-glucose induces oxidative